GlassScriptPhysician profile
Aubrey Welp
NPI 1386109221
$3,145.55
in general payments reported to CMS, 2019-2025
31 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $649 · 2023: $604 · 2024: $1,088 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $393.74 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $264.97 | 2021-2025 | |
| Lilly USA, LLC | $241.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $238.07 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.93 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $206.65 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $131.09 | 2022-2023 | Verquvo, Belsomra |
| Axsome Therapeutics, INC. | $128.03 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $86.68 | 2021-2024 | Trintellix |
| Lundbeck LLC | $80.73 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.50 | 2022-2025 | Jardiance |
| Corium, LLC | $61.60 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $59.38 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $59.07 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alkermes, INC. | $52.74 | 2022-2023 | Aristada, Lybalvi |
| Dexcom, INC. | $44.75 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $44.46 | 2022 | |
| Vanda Pharmaceuticals INC. | $42.86 | 2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $29.62 | 2024 | Quviviq |
| Amarin Pharma, INC. | $28.27 | 2021 | |
| Tris Pharma INC | $20.71 | 2025 | Dyanavel Xr |
| Mylan Specialty L.P. | $20.64 | 2022 | |
| Insulet Corporation | $20.47 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $15.65 | 2024 | Ingrezza |
| Kci USA, INC. | $14.91 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.41 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.24 | 2025 | Voquezna |
| Radius Health, INC. | $13.03 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Welp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.